Multicenter, Single-blind, Adaptive Dose Finding Study of Single Intravenous Injections of BAY 1747846 With Corresponding Blinded Read in Adult Participants With Known or Highly Suspected CNS Lesions Referred for Contrast-enhanced MRI of the CNS
Latest Information Update: 19 Apr 2024
At a glance
- Drugs Gadobutrol (Primary) ; Gadoquatrane (Primary)
- Indications CNS cancer; CNS disorders
- Focus Diagnostic use
- Sponsors Bayer
Most Recent Events
- 22 Nov 2023 According to a Bayer media release, results from this trial will be presented at the 2023 Radiological Society of North America (RSNA) Annual Meeting, taking place from November 26 to 30 in Chicago, USA.
- 13 Dec 2022 Status changed from recruiting to completed.
- 08 Nov 2022 Status changed from active, no longer recruiting to recruiting.